Regulatory T cells (Tregs) are T cells that function to regulate other cells in the immune system through various contact-dependent and independent mechanisms. They are vital in preventing and controlling excessive immune responses and autoimmunity. As of 2022, there is no approved marketed product available in the global market for Regulatory T-Cell Therapies. Based on our estimates, The Regulatory T-Cell (Tregs) Therapies Market is valued at 136.6 Million in 2025 and is predicted to reach 1138.6 Million by the year 2030 at a 58.2 % CAGR during the forecast period for 2025-2030.
The multiple factors driving the growth of the Regulatory T-Cell Therapies (Tregs) Market include the rising chronic conditions such as autoimmune diseases, allergies, & organ transplantation, increasing technological advances in therapy techniques, surging demand for cost-efficient immunotherapies, growing awareness among people regarding the advantages of T-cell therapeutics, and increasing government support for the R&D of innovative regulatory T-cell therapies. Besides, viral infections such as the recent COVID-19 outbreak have expanded the scope of T-cell therapy treatments. The companies operating in this market are collaborating with technologies companies to develop & commercialize Treg therapies. For instance, in September 2021, Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, collaborated with Genentech to develop and commercialize allogeneic T cell therapies and to treat multiple oncology indications. Therefore, increasing collaborations are projected to accelerate market expansion in the future.
However, the cost of regulatory T-cell therapies, poor reimbursement policies for cell therapies, side effects associated with these therapies, and the complicated production and supply chain methods may impede the market growth in the upcoming years.
Market Segmentation
The Regulatory T-Cell Therapies (Tregs) Market is classified based on target indication, products, and region. By target indication, the market is divided into crohn's disease, bipolar disorder, allergic rhinoconjunctivitis, COVID 19, diabetes mellitus, systemic lupus erythematosus, alzheimer disease, graft vs. host disease. By-products, the market is segmented into Tregs, interleukin 2, monoclonal antibodies, small molecules, and other products. The Tregs segment is expected to dominate this market during the forecast years due to its increasing therapeutic applications. Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.
North America had the highest market share in 2020. It is anticipated to dominate the Regulatory T-Cell Therapies (Tregs) Market over the forecast period (2025-2030), owing to the increasing pharmaceutical R&D expenditure and the rising number of clinical trials for T-cell therapies in this region.
Competitive Landscape
Some major key players in the Regulatory T-Cell (Tregs) Therapies Market:
- Abata Therapeutics (US),
- Cellenkos Inc (US),
- Coya Therapeutics (US),
- Roche (Switzerland),
- Caladrius Biosciences (US),
- Sonoma Biotherapeutics (US),
- Nektar Therapeutics (US),
- Eli Lilly and Company (US),
- REGiMMUNE (US),
- Miltenyi Biotec (Germany),
- TeraImmune (US),
- TRACT Therapeutics (US),
- VT Bio (South Korea),
- Amgen (US),
- Sangamo Therapeutics (TxCell) (US),
- Pfizer Inc. (US), PolTREG S.A.. (Poland),
- Parvus Therapeutics (Canada), ILTOO Pharma (France),
- Philogen S.p.A. (Italy),
- Celgene (US),
- AHEAD THERAPEUTICS S.L. (Spain),
- Others
The Regulatory T-Cell (Tregs) Therapies Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 136.6 Million |
|
Revenue Forecast In 2031 |
USD 1138.6 Million |
|
Growth Rate CAGR |
CAGR of 58.2 % from 2025 to 2030 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2025 to 2030 |
|
Historic Year |
|
|
Forecast Year |
2025-2030 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Target Indication, By Product |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Abata Therapeutics (US), Cellenkos Inc (US), Coya Therapeutics (US), Roche (Switzerland), Caladrius Biosciences (US), Sonoma Biotherapeutics (US), Nektar Therapeutics (US), Eli Lilly and Company (US), REGiMMUNE (US), Miltenyi Biotec (Germany), TeraImmune (US), TRACT Therapeutics (US), VT Bio (South Korea), Amgen (US), Sangamo Therapeutics (TxCell) (US), Pfizer Inc. (US), PolTREG S.A.. (Poland), Parvus Therapeutics (Canada), ILTOO Pharma (France), Philogen S.p.A. (Italy), Celgene (US), AHEAD THERAPEUTICS S.L. (Spain), and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
